Kraus Carl N 4
4 · Aceragen, Inc. · Filed Jan 19, 2023
Insider Transaction Report
Form 4
Aceragen, Inc.ACGN
Kraus Carl N
Chief Medical Officer
Transactions
- Exercise/Conversion
Options (Right to Buy)
2023-01-17+440,844→ 440,844 totalExercise: $208.76Exp: 2032-02-09→ Common Stock (440,844 underlying)
Footnotes (3)
- [F1]On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration.
- [F2]The option vests 25% on October 25, 2022, and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
- [F3]Reflects a 1-for-17 reverse stock split, which became effective on January 17, 2023 at 4:59 pm Eastern Time.